在急性髓性白血病中准特定的PI3Kɣ-Akt信号模块,使用异构功能降解分子降解剂
Lois M Kelly1, Justine C Rutter2, Kevin H Lin2
1INSERM UMR 944, IRSL, Saint-Louis Hospital, Paris Cité University, Paris, France.
Nature cancer
|May 30, 2024
概括
在急性髓性白血病 (AML) 中准PIK3CG/p110γ-PIK3R5/p101通路可以抑制癌细胞的生长. 一个新的PROTAC分子有效降解PIK3CG,提供了一个有前途的新AML治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 针对性癌症疗法面临剂量限制性毒性,由于非特定的目标参与.
- 限制组织或限制瘤的点可以减轻毒性并提高治疗效率.
- PIK3CG/p110γ-PIK3R5/p101轴与急性髓性白血病 (AML) 的发生有关.
研究的目的:
- 研究PIK3CG/p110γ-PIK3R5/p101轴在AML中的作用.
- 评估针对AML治疗这一轴的有效性.
- 为AML开发新的治疗策略.
主要方法:
- 在AML细胞中对PIK3CG/p110γ或PIK3R5/p101进行基因沉默.
- 对蛋白质激酶B/Akt信号抑制的评估.
- 开发和测试一个向PIK3CG的蛋白质溶解向嵌合体 (PROTAC).
- 在AML模型中评估PROTAC单独和与venetoclax结合的疗效.
主要成果:
- 抑制PIK3CG/p110γ-PIK3R5/p101轴抑制了Akt信号传递,并影响了AML细胞的适应性.
- 沉默PIK3CG/p110γ或PIK3R5/p101使AML细胞对现有疗法的敏感.
- 现有的PIK3CG抑制剂缺乏持续的抗白血病作用.
- 开发的PROTAC分子有效降解PIK3CG并抑制AML的进展.
结论:
- 在AML中,PIK3CG/p110γ-PIK3R5/p101轴是一个可行的治疗点.
- 一种新的PIK3CG降解PROTAC显示出强大的抗白血病活性.
- 这种PROTAC代表了一种有前途的新治疗方法,用于单独或组合治疗的AML.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K


